Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms od Greenfield, G, McPherson, S, Smith, J, Mead, A, Harrison, C, Mills, K, McMullin, MF

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial od McIlroy, G, Gaskell, C, Jackson, A, Yafai, E, Tasker, R, Thomas, C, Fox, S, Boucher, R, Ghebretinsea, F, Harrison, C, Mead, AJ, McMullin, MF

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib od O'Sullivan, JM, Hamblin, A, Yap, C, Fox, S, Boucher, R, Panchal A, Alimam, S, Dreau, H, Howard, K, Ware, P, Cross, NCP, McMullin, MF, Harrison, CN, Mead, AJ

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies od Mesa, RA, Hudgens, S, Floden, L, Harrison, CN, Palmer, J, Gupta, V, McLornan, DP, McMullin, MF, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, ML, Mead, AJ, Ross, DM, Oh, ST, Perkins, A, Leahy, MF, Deheshi, S, Donahue, R, Klencke, BJ, Verstovsek, S

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic od Verstovsek, S, Chen, C-C, Egyed, M, Ellis, M, Fox, L, Goh, YT, Gupta, V, Harrison, C, Kiladjian, J-J, Lazaroiu, MC, Mead, A, McLornan, D, McMullin, MF, Oh, ST, Perkins, A, Platzbecker, U, Scheid, C, Vannucchi, A, Yoon, S-S, Kowalski, MM, Mesa, RA

Diagnosis and evaluation of prognosis of myelofibrosis: a British Society for Haematology Guideline od McLornan, DP, Godfrey, AL, Green, A, Frewin, R, Arami, S, Brady, J, Butt, NM, Cargo, C, Ewing, J, Francis, S, Garg, M, Harrison, C, Innes, A, Khan, A, Knapper, S, Lambert, J, Mead, A, McGregor, A, Neelakantan, P, Psaila, B, Somervaille, TCP, Woodley, C, Nangalia, J, Cross, NCP, McMullin, MF

Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial od Harrison, CN, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, AC, Geyer, HL, Mesa, RA, Dunn, WG, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, EJ, McMullin, MF, Mead, AJ

Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm od Salisbury, RA, Curto-Garcia, N, O'Sullivan, J, Chen, F, Polzella, P, Godfrey, AL, Russell, J, Knapper, S, Willan, J, Frewin, R, Joshi, S, Arami, S, Burns, S, Teh, CH, Wadelin, F, Dhanapal, J, Neelakantan, P, Milojkovic, D, Psaila, B, Szydlo, R, Francis, S, Cargo, C, Jain, M, McGregor, A, Wallis, L, Duncombe, A, Hussein, H, Dyer, P, Munro, L, Bond, L, McMullin, MF, Somervaille, TCP, Garg, M, Sekhar, M, Harrison, C, Mead, AJ, Innes, AJ

Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis od Fang, Z, Corbizi Fattori, G, McKerrell, T, Boucher, RH, Jackson, A, Fletcher, RS, Forte, D, Martin, J-E, Fox, S, Roberts, J, Glover, R, Harris, E, Bridges, HR, Grassi, L, Rodriguez-Meira, A, Mead, AJ, Knapper, S, Ewing, J, Butt, NM, Jain, M, Francis, S, Clark, FJ, Coppell, J, McMullin, MF, Wadelin, F, Narayanan, S, Milojkovic, D, Drummond, MW, Sekhar, M, ElDaly, H, Hirst, J, Paramor, M, Baxter, EJ, Godfrey, AL, Harrison, CN, Méndez-Ferrer, S